Asia Green Biotechnology (ASIA.CN) Action Cours

Asia Green Biotechnology Corp, trading under the ticker ASIA.CN with ISIN CA04522C1041, is a company based in Calgary, Canada. The company went public via an IPO on January 24, 2019. Asia Green Biotechnology Corp is described as an early-stage international agri-technology company. It focuses on the development, evaluation, testing, application, and supply of proprietary organic hybridization technology. The company is headquartered in Calgary, Alberta. It operates under license agreements with InPlanta Biotechnology Inc. for the planting, growth, and harvesting of hemp and related crops. Additionally, it has license agreements with Swysh Inc. and Pathway Rx Corp for the evaluation and development of medicinal and cannabinoid extracts. The company is in the process of establishing research and development programs in Cambodia and Thailand, with ongoing evaluation of potential expansion into other countries in the region. Its website is http://asiacannabiscorp.com/. The company operates in the agri-technology sector, though specific sector and industry details are listed as N/A in its profile. Asia Green Biotechnology Corp is engaged in the cultivation of hemp and related crops, as well as the development of cannabinoid-based products, leveraging its proprietary technology. The company's activities are centered around the commercialization of organic hybridization technology and its derived products. It is not clear from the provided information whether the company has any significant revenue streams or financial performance metrics, as these details are not included in the source description. The company's focus on international expansion, particularly in Southeast Asia, indicates a strategic direction towards global market opportunities in the agricultural and biotechnology fields.